Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
AVNS

Avanos Medical Inc

AVNS

21.50USD+0.28 (+1.32%)Market Closed
Watchlist

Market Summary

USD21.50+0.28
Market Closed
1.32%

AVNS Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

AVNS Stock Price

View Fullscreen

AVNS RSI Chart

AVNS Valuation

Market Cap

985.1M

Price/Earnings (Trailing)

-17.78

Price/Sales (Trailing)

1.29

EV/EBITDA

13.58

Price/Free Cashflow

18.45

AVNS Price/Sales (Trailing)

AVNS Profitability

EBT Margin

4.41%

Return on Equity

-2.92%

Return on Assets

-2.16%

Free Cashflow Yield

5.42%

AVNS Fundamentals

AVNS Revenue

Revenue (TTM)

766.0M

Revenue Y/Y

-15.24%

Revenue Q/Q

1.12%

AVNS Earnings

Earnings (TTM)

-55.4M

Earnings Y/Y

-123.57%

Earnings Q/Q

94.57%

Price Action

Last 7 days

-0.6%

Last 30 days

20.0%

Last 90 days

-1.0%

Trailing 12 Months

-20.3%

How does AVNS drawdown profile look like?

AVNS Financial Health

Current Ratio

3.16

Debt/Equity

0.16

Debt/Cashflow

0.26

AVNS Investor Care

Buy Backs (1Y)

0.15%

Diluted EPS (TTM)

-1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023798.3M796.8M766.0M0
2022761.3M745.8M763.8M804.0M
2021715.1M737.8M736.2M744.6M
2020713.8M705.3M719.6M714.8M
2019660.1M671.4M677.7M697.6M
2018622.3M634.1M648.7M652.3M
2017577.5M588.9M600.3M611.6M
2016523.3M537.6M551.9M566.2M
20151.7B1.6B1.6B509.0M
20141.7B1.7B1.7B1.7B
20131.7B1.7B1.7B1.7B
20120001.7B

Latest Insider Trading transactions for AVNS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 30, 2023
hurley john joseph
sold (taxes)
-10,009
17.81
-562
principal accounting officer
Jul 20, 2023
james mojirade
sold (taxes)
-17,337
26.15
-663
svp, general counsel
May 08, 2023
woody joseph fralin
sold (taxes)
-1,372,430
23.97
-57,256
chief executive officer
May 08, 2023
holbrook kerr
sold (taxes)
-42,474
23.97
-1,772
svp, chief commercial officer
May 08, 2023
greiner michael
sold (taxes)
-352,599
23.97
-14,710
svp - chief financial officer
Mar 06, 2023
james mojirade
acquired
-
-
20,339
svp, general counsel
Mar 06, 2023
sarker arjun ranjan
acquired
-
-
4,562
senior vp, international
Mar 06, 2023
greiner michael
acquired
-
-
36,350
svp - chief financial officer
Mar 06, 2023
holbrook kerr
sold (taxes)
-44,815
29.62
-1,513
svp, gm chronic care
Mar 06, 2023
hurley john joseph
sold (taxes)
-947
29.62
-32.00
principal accounting officer

1–10 of 50

Which funds bought or sold AVNS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-51.23
-791,988
497,514
-%
Nov 22, 2023
KBC Group NV
unchanged
-
-
92,000
-%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-30.06
-945,838
1,171,420
0.01%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-478,253
-
-%
Nov 21, 2023
Walleye Capital LLC
new
-
339,433
339,433
-%
Nov 21, 2023
COMERICA BANK
new
-
571,197
571,197
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-220,404
-
-%
Nov 16, 2023
Creative Planning
new
-
5,076
5,076
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-732
-
-%
Nov 15, 2023
JANE STREET GROUP, LLC
sold off
-100
-293,352
-
-%

1–10 of 50

Latest Funds Activity

Are funds buying AVNS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVNS
No. of Funds

Schedule 13G FIlings of Avanos Medical Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
rgm capital, llc
5.71%
2,653,104
SC 13G/A
Feb 09, 2023
vanguard group inc
11.83%
5,500,000
SC 13G/A
Feb 08, 2023
paradice investment management llc
5.0%
2,343,232
SC 13G/A
Jan 26, 2023
blackrock inc.
16.3%
7,571,048
SC 13G/A
Jan 20, 2023
blackrock inc.
16.3%
7,571,048
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
0.2%
133,980
SC 13G/A
Feb 11, 2022
champlain investment partners, llc
2.44%
1,174,483
SC 13G/A
Feb 11, 2022
rgm capital, llc
6.08%
2,930,872
SC 13G
Feb 09, 2022
vanguard group inc
10.84%
5,221,786
SC 13G/A
Feb 04, 2022
wellington management group llp
2.75%
1,325,674
SC 13G/A

Recent SEC filings of Avanos Medical Inc

View All Filings
Date Filed Form Type Document
Nov 01, 2023
8-K
Current Report
Nov 01, 2023
10-Q
Quarterly Report
Oct 31, 2023
4
Insider Trading
Oct 02, 2023
8-K
Current Report

Peers (Alternatives to Avanos Medical Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
178.8B
40.0B
10.05% -2.88%
34.63
4.47
-11.26% -34.57%
71.3B
19.4B
-6.71% 1.22%
44.09
3.79
2.66% -16.58%
18.4B
15.0B
11.91% -35.29%
7.11
1.23
3.01% 209.09%
16.8B
3.8B
-13.48% 11.82%
46.33
4.42
-1.48% -28.97%
MID-CAP
9.1B
12.6B
2.80% -13.35%
19.86
0.72
-0.94% -29.54%
8.9B
2.7B
7.69% -22.67%
-56.07
3.28
-3.01% 97.36%
8.4B
3.4B
4.90% 20.89%
30
2.45
3.13% 18.17%
6.6B
3.9B
-1.54% 1.10%
-30.43
1.69
-2.62% 73.28%
3.1B
6.5B
5.03% 11.86%
14.6
0.48
1.83% 10.70%
2.9B
342.6M
11.80% -12.52%
-240.39
8.41
42.19% 84.14%
SMALL-CAP
1.2B
3.1B
19.36% -60.32%
-2.73
0.37
7.95% -550.16%
310.6M
163.3M
13.17% -30.31%
-12.64
1.9
7.14% -56.09%
280.7M
335.9M
7.28% -49.08%
43.55
0.84
4.71% 116.39%
88.3M
50.3M
4.17% 45.35%
-5.83
1.76
3.23% 20.81%
4.2M
3.8M
13.42% -61.23%
-0.36
1.11
17.30% 10.67%

Avanos Medical Inc News

Latest updates
Defense World27 Nov 202310:57 am13 hours ago
Zacks Investment Research02 Nov 202307:00 am25 days ago
Houston Chronicle 01 Nov 202307:00 am26 days ago
Investing.com UK01 Nov 202307:00 am26 days ago
Yahoo Finance31 Oct 202307:00 am27 days ago
Nasdaq27 Oct 202307:00 am31 days ago
Nasdaq26 Oct 202307:00 am32 days ago
Nasdaq25 Oct 202307:00 am33 days ago
Yahoo Finance02 Oct 202307:00 am56 days ago
Yahoo Finance11 Aug 202307:00 am3 months ago
Zacks Investment Research26 Jul 202307:00 am4 months ago
Yahoo Finance25 Jul 202307:00 am4 months ago
Nasdaq19 Jul 202307:00 am4 months ago

Financials for Avanos Medical Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue1.1%171,300,000169,400,000191,700,000233,550,000202,100,000170,900,000197,400,000193,400,000184,100,000186,400,000180,700,000185,000,000185,700,000163,700,000180,400,000189,800,000171,400,000172,200,000164,200,000169,900,000165,100,000
Gross Profit-2.4%95,500,00097,800,000104,500,000124,300,000110,100,000101,600,000106,600,00098,750,00090,200,00085,700,00091,300,00086,500,00095,800,00086,500,000102,100,000109,700,00095,000,00098,700,00098,800,000100,400,000104,700,000
  S&GA Expenses-15.4%78,700,00093,000,00092,700,00084,550,00082,100,00083,200,00090,100,00075,200,00075,000,00076,700,00073,400,00082,200,00082,400,00076,900,00091,100,000103,600,00094,400,00094,700,000106,400,00087,900,00086,300,000
  R&D Expenses-10.3%6,100,0006,800,0007,900,0007,700,0007,300,0007,600,0007,800,0007,600,0008,400,0008,000,0008,300,0009,600,0008,200,0007,700,0009,400,0008,400,0009,600,0009,500,00010,200,00010,600,00010,500,000
EBITDA Margin-100.0%-0.120.150.150.150.130.080.06-0.04-0.04-0.010.000.05-0.01-0.01-0.02-----
Interest Expenses34.3%4,700,0003,500,0003,500,0003,000,0003,000,0002,700,0001,300,000700,000900,000900,000800,0002,700,0004,300,0004,300,0004,300,0004,300,0003,500,0003,500,0003,700,0003,500,0004,200,000
Income Taxes875.0%6,200,000-800,000100,0008,350,000300,0002,800,0001,900,00014,800,00038,000,000-46,000,000-5,800,000-800,000-23,500,000-2,900,000-6,700,000-400,000-8,800,000-3,300,000-5,600,000-6,700,000800,000
Earnings Before Taxes49.0%-2,600,000-5,100,000-400,00029,100,00016,000,0007,600,0007,300,00026,300,0002,700,000-7,500,000-14,200,000-49,800,000-4,200,000---6,500,000-20,300,000-11,300,000-25,900,000-9,400,0005,000,000
EBT Margin-100.0%-0.040.070.080.080.070.040.01-0.09-0.10-0.08-0.08-0.03-0.09-0.09-0.09-----
Net Income94.6%-3,700,000-68,100,000-500,00016,900,00015,700,00012,500,0005,400,00011,500,000-35,300,00038,500,000-8,400,000-49,000,00019,300,000-3,000,0003,700,000-6,100,000-11,500,000-8,000,000-20,300,000-2,200,0004,200,000
Net Income Margin100.0%--0.050.050.060.06-0.010.020.01-0.070.00-0.05-0.040.02-0.02-0.03-0.07-----
Free Cashflow100.0%--2,600,000-6,800,00033,700,00028,400,00027,000,0001,800,00052,100,00023,200,00015,300,000-3,300,0001,100,0001,100,0001,100,000-5,800,000-2,900,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets3.5%1,7251,6671,7351,7871,7751,7531,7671,6041,5981,6831,6491,6731,7991,7561,7641,8001,8081,7831,8341,8331,845
  Current Assets3.5%525507454500470437439428405444448467568517524539547573660714737
    Cash Equivalents30.9%10782.0096.0012811710710411998.00100100112180185188205214288348385412
  Inventory5.6%157148200132194169158159158160165169184174153146145134130121121
  Net PPE-4.7%117123164119163164167168170172173175177179179185182174160154137
  Goodwill3.8%79276382276082482582680280280380280380180080080119.0014.00784784787
Liabilities16.4%503432436496512501510333336387396416509494507534541507554536544
  Current Liabilities6.4%171161159186162151153139129158155166179176189213218187238264266
  Long Term Debt27.1%258203205226248249254130145165175180249248248248248248248248-
    LT Debt, Current0%6.006.006.006.006.005.00---------------
    LT Debt, Non Current----226---130-------248---248248
Shareholder's Equity-1.0%1,2221,2351,2991,2911,2641,2591,2631,2711,2671,3021,2571,2621,2901,2621,2571,2731,2671,2771,2801,2971,300
  Retained Earnings-1.2%-325-321-253-253-270-293-304-303-320-285-323-309-268-287-284-288-282-270-262-242-240
  Additional Paid-In Capital0.3%1,6601,6551,6511,6461,6421,6371,6331,6291,6261,6211,6171,6091,6041,6001,5961,5941,5921,5871,5831,5781,576
Shares Outstanding-0.9%46.0047.0047.0047.0046.0047.0047.0048.0048.0048.0048.0048.0048.0048.0048.0048.0048.0048.0048.0047.0047.00
Cashflow (Last 12 Months)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations1219.2%29,100-2,600-6,80033,70028,40027,0001,80052,10023,20015,300-3,3001,1001,1001,100-5,800-2,900-16,600-31,900-23,100-7,400-67,800
  Share Based Compensation0%3,9003,9004,0004,0004,1004,0003,8003,0003,5003,6003,1003,2003,4003,0002,5001,7002,8001,8004,2002,5002,400
Cashflow From Investing-652.3%-48,900-6,500-4,000-4,900-4,700-4,100-121,700-4,700-4,800-5,800-5,700-5,100-7,000-6,900-5,200-8,100-57,600-29,900-12,500-17,800-56,500
Cashflow From Financing1239.0%46,700-4,100-22,100-21,900-10,200-16,900105,700-25,800-19,200-10,100-200-68,300-2,000300--1002,500800-1,700-1,6005,400
  Buy Backs253.8%9,2002,6001,10040011,00014,70019,40010,900100500-500100300-2001001,4001,900300-

AVNS Income Statement

2023-09-30
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net Sales$ 171.3$ 172.3$ 500.0$ 502.5
Cost of products sold75.872.1215.3211.2
Gross Profit95.5100.2284.7291.3
Research and development6.17.120.422.0
Selling and general expenses78.778.3260.5247.8
Other expense, net9.52.010.82.6
Operating Income (Loss)1.212.8(7.0)18.9
Interest income0.90.31.90.5
Interest expense(4.7)(3.0)(11.7)(7.0)
(Loss) Income Before Income Taxes(2.6)10.1(16.8)12.4
Income tax (provision) benefit(6.2)0.9(4.1)(0.6)
(Loss) Income from Continuing Operations(8.8)11.0(20.9)11.8
Income (loss) from discontinued operations, net of tax5.14.7(51.4)21.8
Net (Loss) Income$ (3.7)$ 15.7$ (72.3)$ 33.6
Basic (Loss) Earnings Per Share    
Continuing operations- basic (in dollars per share)$ (0.19)$ 0.24$ (0.45)$ 0.25
Discontinued operations- basic (in dollars per share)0.110.10(1.10)0.46
Basic (Loss) Earnings Per Share (in dollars per share)(0.08)0.34(1.55)0.71
Diluted (Loss) Earnings Per Share    
Continuing operations- diluted (in dollars per share)(0.19)0.23(0.45)0.25
Discontinued operations- diluted (in dollars per share)0.110.10(1.10)0.46
Diluted (Loss) Earnings Per Share (in dollars per share)$ (0.08)$ 0.33$ (1.55)$ 0.71

AVNS Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 107.1$ 127.7
Accounts receivable, net of allowances145.2167.9
Inventories156.6132.3
Prepaid and other current assets13.613.9
Assets held for sale102.158.0
Total Current Assets524.6499.8
Property, Plant and Equipment, net116.8118.6
Operating Lease Right-of-Use Assets27.127.5
Goodwill791.5760.3
Other Intangible Assets, net242.2234.2
Deferred Tax Assets4.34.6
Other Assets18.417.6
Assets Held for Sale0.0124.3
TOTAL ASSETS1,724.91,786.9
Current Liabilities  
Current portion of long-term debt6.26.2
Current portion of operating lease liabilities12.712.0
Trade accounts payable52.167.9
Accrued expenses97.298.9
Liabilities held for sale2.50.8
Total Current Liabilities170.7185.8
Long-Term Debt258.3226.3
Operating Lease Liabilities29.532.5
Deferred Tax Liabilities28.725.4
Other Long-Term Liabilities15.623.5
Liabilities Held for Sale0.02.2
Total Liabilities502.8495.7
Commitments and Contingencies
Stockholders’ Equity  
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued0.00.0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,425,157 outstanding as of September 30, 2023 and 46,528,907 outstanding as of December 31, 20220.50.5
Additional paid-in capital1,659.71,646.4
Accumulated deficit(325.4)(253.1)
Treasury stock(79.7)(66.8)
Accumulated other comprehensive loss(33.0)(35.8)
Total Stockholders’ Equity1,222.11,291.2
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 1,724.9$ 1,786.9
AVNS
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy and OrthogenRx's knee osteoarthritis pain relief injection products. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEavanos.com
 EMPLOYEES4044

Avanos Medical Inc Frequently Asked Questions


What is the ticker symbol for Avanos Medical Inc?

Ticker symbol for Avanos Medical Inc is AVNS.

What is the market capital of Avanos Medical Inc (AVNS)?

As of Fri Nov 24 2023, market cap of Avanos Medical Inc is 985.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVNS stock?

You can check AVNS's fair value in chart. The fair value of Avanos Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avanos Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVNS so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Avanos Medical Inc stock overpriced or underpriced?

The fair value guage provides a quick view whether AVNS is over valued or under valued. Whether Avanos Medical Inc is cheap or expensive depends on the assumptions which impact Avanos Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVNS.

What is Avanos Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 24 2023, AVNS's PE ratio (Price to Earnings) is -17.78 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVNS PE ratio will change depending on the future growth rate expectations of investors.